Merus is a clinical stage biotechnology company based in Utrecht, The Netherlands, that develops innovative therapeutics to address serious unmet needs in oncology.

Human Biclonics® for Superior Clinical Efficacy

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.